Company Information
USD
159.39
- (-1%)
NASDAQ:ASND, ASCENDIS PHARMA A/S
Industry: Biotechnology
End of Day: 8 May 2025 GMT-4
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
Address
Tuborg Boulevard 12
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Dr. Albert Cha, M.D.,PhD
Chairman of the Board/Director
Mr. Michael Wolff Jensen
Chief Legal Officer/Executive VP
Mr. Jan Moller Mikkelsen
CEO/Co-Founder/Director/President
Mr. Peter Rasmussen
Chief Accounting Officer/Vice President, Divisional
Ms. Lotte Sonderbjerg
Chief Administrative Officer/Executive VP
Ms. Lisa Bright
Director
Mr. Flemming Steen Jensen
Executive VP, Divisional
Dr. Kennett Sprogoe, PhD
Executive VP/Other Corporate Officer
Mr. Scott T Smith
CFO/Executive VP
Mr. William Carl Fairey
Director
Mr. Lars Holtug
Director
Dr. Stina Singel, M.D.
Executive VP/Other Corporate Officer
Ms. Siham Imani
Director
Ms. Camilla Harder Hartvig
Other Executive Officer
Ownership
Institution Holdings
RA Capital Management, LLC
10,107,400 (17.853%)
RA Capital Management, LP
10,107,400 (17.853%)
Artisan Partners Limited Partnership
5,749,227 (10.155%)
FMR LLC
5,229,070 (9.236%)
FMR Inc
5,114,369 (9.034%)
Westfield Capital Management Company, LP
4,030,634 (7.119%)
HHG PLC
3,994,785 (7.056%)
T. Rowe Price Investment Management,Inc.
3,989,830 (7.047%)
venBio Select Advisor LLC
3,755,555 (6.634%)
Wellington Management Company LLP
3,248,293 (5.738%)
Funds Holdings
Vanguard Health Care Fund
2,136,431 (3.774%)
MFS Mid Cap Growth Equity
1,173,339 (2.073%)
T. Rowe Price US Mid-Cap Growth Equity
1,141,900 (2.017%)
T. Rowe Price Mid-Cap Growth Fund
1,141,900 (2.017%)
Artisan Mid Cap Fund
1,117,826 (1.974%)
Artisan U.S. Mid-Cap Growth
1,117,826 (1.974%)
Janus Mid Cap Growth Tr
1,043,428 (1.843%)
Janus Henderson Enterprise Fund
1,043,428 (1.843%)
Fidelity Select Health Care Portfolio
870,000 (1.537%)
T. Rowe Price New Horizons Fund
776,147 (1.371%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
